Prevent Cancer Preclinical Drug Development Program - a Novel Multi-Antigen Vaccine (tnbcvax) to Prevent Triple Negative Breast Cancer
Contract Overview
Contract Amount: $1,107,542 ($1.1M)
Contractor: University of Oklahoma
Awarding Agency: Department of Health and Human Services
Start Date: 2021-09-16
End Date: 2025-11-15
Contract Duration: 1,521 days
Daily Burn Rate: $728/day
Official Description: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM - A NOVEL MULTI-ANTIGEN VACCINE (TNBCVAX) TO PREVENT TRIPLE NEGATIVE BREAST CANCER
Place of Performance
Location: Oklahoma, 73104
State: Oklahoma Government Spending